Evidence map›Paper›PMID 32282022›Full record

ReviewJAMA2020

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

James M Sanders, Marguerite L Monogue, Tomasz Z Jodlowski, James B Cutrell

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04480593 (The Use of Brazilian Green Propolis Extract), which is not on this map. Cited by 1,441 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,441citing papers in PubMed, 11 pooled it
59.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04480593 phase2 / phase3completednot on this map

The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.

TypeinterventionalSponsorD'Or Institute for Research and EducationRan2020 to 2020Enrolled120ConditionsCovid19ArmsBrazilian Green Propolis Extract (EPP-AF), Standard care
3 · Its place in the literature

Who cites it

1,441 citing papers in PubMed, 11 syntheses or guidelines pooled it, 2,458 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Scientifica · 2026
    Article
  20. Review

1,381 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

James M SandersDepartment of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
Marguerite L MonogueDepartment of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
Tomasz Z JodlowskiPharmacy Service, VA North Texas Health Care System, Dallas.
James B CutrellDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
The University of Texas Southwestern Medical Center · USVA North Texas Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceThe pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. OBSERVATIONS: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. CONCLUSIONS AND RELEVANCE: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.

Indexed as

BetacoronavirusAdenosine MonophosphateAdrenal Cortex HormonesAlanineAmidesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntiviral AgentsAzithromycinChloroquineCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentHumansHydroxychloroquineImmunoglobulinsAdenosine MonophosphateAdrenal Cortex HormonesAlanineAmidesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntiviral AgentsAzithromycinChloroquinefavipiravirHydroxychloroquineImmunoglobulinsImmunologic FactorsIndolesLopinavirOseltamivirPyrazinesremdesivirRibavirinRitonavirSulfidesumifenovir

Identifiers

PMID32282022
OpenAlexW3016084006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.